|Bid||0.00 x 1400|
|Ask||0.00 x 1100|
|Day's range||222.87 - 226.66|
|52-week range||129.21 - 235.85|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||33.46|
|Forward dividend & yield||3.40 (1.50%)|
|1y target est||216.36|
A week before Eli Lilly disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters. On April 8, a group of employees filed an anonymous complaint internally alleging that an executive at its Branchburg, New Jersey, factory had altered documents required by the U.S. Food and Drug Administration. As Reuters reported last month, Lilly tapped the Washington D.C. law firm Covington & Burling LLP to investigate the alleged alterations, which the employees said were meant to downplay serious quality control problems at the plant producing the drugmaker's COVID-19 antibody treatment.
2. Small business outlook
Eli Lilly (NYSE:LLY) shares were up in double digits Monday on hope that its therapy for treating Alzheimer’s will soon get the approval of the U.S. drugs regulator. The strength in the drugmaker’s shares followed the Food and Drug Administration’s nod for rival Biogen's (NASDAQ:BIIB) aducanumab, the first time in nearly 20 years that the regulator has approved a medicine to treat the fatal illness. Alzheimer’s is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually, the ability to carry out simple tasks.